Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies
Small Molecule-Induced, Selective STAT3 Degradation Leads to Anti-Tumor Activity in STAT3-Dependent Heme Malignancies
1 PagesTargeted protein degradation is a new therapeutic modality that expands the ability to target difficult-to-drug oncogenic proteins. Targeted protein degradation is a new therapeutic modality that expands the ability to target difficult-to-drug oncogenic proteins. Kymera Therapeutics is developing degraders of STAT3 with drug-like properties,represented here with KYM-003 and its analog compound A. These compounds potently and selectively degrade STAT3 protein and display strong anti-tumor activity in models of heme malignancies.
